Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 3/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32670068 | 0.87 | KDM4E (0.37) | LTB4RLTB4R2KDM4EATMALDH1A1 | |
| SCHEMBL32669627 | 0.82 | FTO (0.43) | LTB4RLTB4R2KDM4EALDH1A1 | |
| SCHEMBL32670048 | 0.82 | SMN1; SMN2 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL32669930 | 0.81 | RAB9A (0.38) | KDM4EATMALDH1A1LMNAESR1 | |
| SCHEMBL32669759 | 0.79 | PORCN (0.36) | KDM4EESR1 | |
| SCHEMBL32669969 | 0.78 | FTO (0.50) | KDM4EALDH1A1LMNA | |
| SCHEMBL32669571 | 0.77 | SLC22A12 (0.36) | KDM4EESR1 | |
| SCHEMBL32669598 | 0.74 | COMT (0.32) | KDM4EALDH1A1 | |
| SCHEMBL32669726 | 0.72 | SLC22A12 (0.39) | LTB4RLTB4R2SIGMAR1 | |
| SCHEMBL32669541 | 0.71 | TTR (0.44) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | LTB4R 2428/4885LTB4R2 3555/4885KDM4E 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.